SCOTTSDALE, AZ--(Marketwire - September 24, 2008) - ImmuneRegen BioSciences, Inc., a wholly owned subsidiary of IR BioSciences Holdings, Inc. (OTCBB: IRBS), will present pre-clinical study results that indicate that its drug candidate Viprovex® enhances the safety and efficacy of Tamiflu® (manufactured by Hoffmann-La Roche Inc.) in treating influenza at the 2008 Biomedical Advanced Research and Development Authority (BARDA) Industry Day. Heidi L. Pinyerd, scientific program manager at ImmuneRegen, will display findings in the poster entitled, "Viprovex Enhances Tamiflu Safety/Efficacy in Influenza A/H3N2 Exposed Cotton Rat" at 6 p.m., Sept. 24 and 25th, at the Crystal Gateway Marriott, Arlington, Va.
